TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02599103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fried soybean oil
Description: participants drinks the milk shakes prepared from 60g of fried soybean oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palm oil
Description: participants drinks the milk shakes prepared from 60g of palm oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fried palm oil
Description: participants drinks the milk shakes prepared from 60g of fried palm oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camellia oil
Description: participants drinks the milk shakes prepared from 60g of camellia oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fried camellia oil
Description: participants drinks the milk shakes prepared from 60g of fried camellia oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tallow
Description: participants drinks the milk shakes prepared from 60g of tallow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fried tallow
Description: participants drinks the milk shakes prepared from 60g of fried tallow
Study: NCT02291432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous muscle-derived cells (AMDC)
Description: Cell treatment
Study: NCT04464616

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anaesthesia
Description: spinal anaesthesia will be performed with the patient in sitting position at the L3-L4 or L4-L5 interspaces with a 25 or 27 G spinal tip needle with the study drug in the total volume of 3 ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anaesthesia
Description: spinal anaesthesia will be performed with the patient in sitting position at the L3-L4 or L4-L5 interspaces with a 25 or 27 G spinal tip needle with the study drug in the total volume of 3 ml.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: spinal anaesthesia
Description: spinal anaesthesia will be performed with the patient in sitting position at the L3-L4 or L4-L5 interspaces with a 25 or 27 G spinal tip needle with the study drug in the total volume of 3 ml.
Study: NCT01736774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care intervention
Description: The usual care intervention will include appropriate primary care as required including medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Description: Exercise and manipulative therapy treatment for 10 weeks:The treatment intervention consists of two visits per week for the first four weeks (8 treatments) and one visit per week for the last six weeks (6 treatments)
Study: NCT01041846

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
Study: NCT02194712

Intervention type: OTHER
Intervention: Urine CAA detection
Description: In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
Study: NCT01307137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Description: An expert patient in the peer-led intervention will provide effective support for patients and families to accelerate adoption of CER for diabetes prevention and management in the elderly. This will lead to better self-efficacy and clinical outcomes.~Those veterans enrolled in the MOVE! and HARC programs that have showed success in management of weight and Diabetes will be offered to become peer-leaders.~* Weight management success is defined as a loss of at least 5% of the weight since enrollment~* Diabetes management will be defined as adequate control of HbA1c and/ or blood pressure and lipids.~The potentials peer-leaders will have a pre-assessment test to evaluate diabetes prevention and management knowledge and motivation and support skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention
Description: Participants in the TAP group will receive mobile phones that will be programmed to monitor specific clinical parameters and promote adoption of CER on prevention and management of diabetes, with protocols developed in part based on the input from the focus groups. These devices display messages, tips, reminders and questions regarding healthy lifestyle and clinical parameters of diabetes, which will be developed using best practice guidelines. Participants will be asked to respond to the questions daily if they can. Also they are asked to provide their daily weight, blood pressure, and glucose levels (the later only for patients with diabetes).
Study: NCT03799692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1, 8, 15.~Drug: Carboplatin AUC=2 iv, d1, 8, 15.
Study: NCT01880086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
Study: NCT02419612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02849860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-121 Lotion
Description: Lotion
Study: NCT03241628

Intervention type: DEVICE
Intervention: Dressing Glove
Description: Viscose dressing glove
Study: NCT00581347

Intervention type: OTHER
Group type: OTHER
Intervention: outreach services
Description: Tracking/reminder/recall/home visit strategy.
Study: NCT00514644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid ultrasound examination
Description: Ultrasonographic examination of the carotid arteries to determine the grade of carotid stenosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Panorama examination
Description: Examination with the odontological radiological method Panorama, including a frontal verification image
Study: NCT01707355

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: intervention - poster
Study: NCT01665885

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZOLL Thermogard XP
Description: Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution). Cooling catheter placement at the earliest 30min after end of thrombolysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BARD/Medivance Arctic Sun 5000
Description: Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution) and simultaneous start of surface cooling.
Study: NCT04274244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML
Description: Regenerative periodontal therapy + Cross-linked hyaluronic acid 1.8%:~* The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~* Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~* Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~* The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~* Application of Hyadent BG® 1,8% filling the bone defect from the bottom upwards in the test group.~* Single internal modified mattress suture (5/0 Vicryl, Ethicon).~* Sutures will be removed after two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enamel Matrix Proteins (Active comparator group)
Description: Regenerative periodontal therapy + Enamel matrix proteins:~* The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~* Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~* Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~* The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~* Application of Emdogain® filling the bone defect from the bottom upwards in the active comparator group.~* Single internal modified mattress suture (5/0 Vicryl, Ethicon).~* Sutures will be removed after two weeks.
Study: NCT01959763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss counseling program
Description: Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss counseling program
Description: Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss counseling program
Description: Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss counseling program
Description: Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss counseling program
Description: Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss counseling program
Description: Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.
Study: NCT02594904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yinzhihuang Oral Liquid
Description: All the four groups will be given same treatment as being described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yinzhihuang Oral Liquid
Description: All the four groups will be given same treatment as being described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yinzhihuang Oral Liquid
Description: All the four groups will be given same treatment as being described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yinzhihuang Oral Liquid
Description: All the four groups will be given same treatment as being described in arm description.
Study: NCT00676312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH134
Study: NCT03374592

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volumetric Intensity-Modulated Arc Therapy
Description: Advanced radiotherapy technique

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiotherapy
Description: Conventional radiotherapy technique
Study: NCT02721810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consideration of 3-month functional prognosis
Study: NCT00790920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: 90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV, single bolus over 1 - 2 minutes on 1st day
Study: NCT02478021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Effects of hydrocortisone compared to placebo on cognition

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: Effects of hydrocortisone compared to placebo on cognition
Study: NCT02732613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway
Description: If there were any conflicts of the Laryngeal Mask Airway classic size selection in slim patients by the actual or ideal body weight, size selection will based on actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway
Description: If there were any conflicts of the Laryngeal Mask Airway classic size selection in slim patients by the actual or ideal body weight, size selection will based on actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.
Study: NCT02560935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea (Moderate Dose)
Description: The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea (Low Dose)
Description: The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
Study: NCT02601898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipoic acid
Description: Vaginal capsules (medical device) containing 10 mg of lipoic acid (1 per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Vaginal capsules (drug) containing 200 mg of progesterone (2 per day)
Study: NCT00793221

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of sirolimus-eluting coronary stent
Description: Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of everolimus-eluting coronary stent
Description: Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
Study: NCT02748694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.
Study: NCT04548115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Condition
Description: Participants in this condition will engage in a 5-weekly 45 minute group-based physical activity session conducted in the community with 15 minutes of preparation/break time (totaling 5 hours of intervention). Physical activity was selected over basic psychosocial care to test the effects of inter-generational contact independent of arts and heritage-based engagements.
Study: NCT02748694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.
Study: NCT00231114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alair System
Description: Treatment of airways with the Alair System

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alair System
Description: Sham treatment of airways with the Alair System
Study: NCT02748694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 tablets or oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-041 Placebo
Description: TAK-041 placebo-matching suspension or tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-041 Placebo
Description: TAK-041 placebo-matching suspension or tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-041 Placebo
Description: TAK-041 placebo-matching suspension or tablet.
Study: NCT00802555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: 360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met
Study: NCT02784470

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gastroduodenal stent placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrojejunostomy
Study: NCT00888901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: eltrombopag tablets daily, in increasing dosage, for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids (Aprednislon)
Description: corticosteroids in decreasing dosage
Study: NCT04268901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung Gear VR
Description: Participants 13 -21 years old can use the Samsung Gear VR. The VE to be used in this study is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merge VR
Description: Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go
Description: Participants 7-21 years can use the Oculus Go. The visual a bright, vibrant color and a quality image. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a handheld remote. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use so that the chance of infection will be minimized.
Study: NCT01554865

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Optifast
Description: 1-2 sachets of Optifast daily as part of diet modification (partial meal replacement diet)
Study: NCT01562535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pronation
Description: In this technique the arm is flexed 90 degrees and a gentle pronation is applied to the arm; then the arm is further flexed to 45 degrees until the clinician feels a click in the elbow meaning the re-accommodation of the radial head has been accomplished.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supination
Description: The affected arm is in a 90 degrees flexion. The clinician will hold the arm by the elbow and then makes a gentle supination of the affected arm and flexion of the elbow until feeling the click and the child is able to move the arm without pain.
Study: NCT04492150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 5%/Nacl 0.3% Inj_#3
Description: 250 mL/hour of dextrose 5% intravenous drip

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 250 mL/hour of normal saline intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 250 mL/hour of normal saline intravenous drip
Study: NCT03657459

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Danger Signs of Heart Failure Videos
Description: Short (under 3 minutes each) videos on (a) recognition of dyspnea, fatigue and edema and (b) self-management of each (based on diet, fluid management and activities)
Study: NCT01554865

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional diet counseling